Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer.
Sayar E, Patel RA, Coleman IM, Roudier MP, Zhang A, Mustafi P, Low JY, Hanratty B, Ang LS, Bhatia V, Adil M, Bakbak H, Quigley DA, Schweizer MT, Hawley JE, Kollath L, True LD, Feng FY, Bander NH, Corey E, Lee JK, Morrissey C, Gulati R, Nelson PS, Haffner MC. Sayar E, et al. Among authors: bander nh. JCI Insight. 2023 Apr 10;8(7):e162907. doi: 10.1172/jci.insight.162907. JCI Insight. 2023. PMID: 36821396 Free PMC article.
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy.
Stangl-Kremser J, Sun M, Ho B, Thomas J, Nauseef JT, Osborne JR, Molina A, Sternberg CN, Nanus DM, Bander NH, Tagawa S. Stangl-Kremser J, et al. Among authors: bander nh. Prostate. 2023 Oct;83(14):1351-1357. doi: 10.1002/pros.24597. Epub 2023 Jul 9. Prostate. 2023. PMID: 37424145
Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591.
Tagawa ST, Thomas C, Sartor AO, Sun M, Stangl-Kremser J, Bissassar M, Vallabhajosula S, Huicochea Castellanos S, Nauseef JT, Sternberg CN, Molina A, Ballman K, Nanus DM, Osborne JR, Bander NH. Tagawa ST, et al. Among authors: bander nh. J Clin Oncol. 2024 Mar 1;42(7):842-851. doi: 10.1200/JCO.23.00573. Epub 2023 Nov 3. J Clin Oncol. 2024. PMID: 37922438 Clinical Trial.
α-Labeling of J591, an Antibody Targeting Prostate-Specific Membrane Antigen: The Technique and Considerations from the First Dedicated Production Lab at an Academic Institution in the United States.
Subramanian K, Stangl-Kremser J, Sawoszczyk L, Avlonitis V, Gernerd A, Nixon K, Zgaljardic M, Tagawa S, Bander N, Osborne JR. Subramanian K, et al. J Nucl Med Technol. 2023 Sep;51(3):215-219. doi: 10.2967/jnmt.122.265166. Epub 2023 Apr 25. J Nucl Med Technol. 2023. PMID: 37163648 Review.
Folate hydrolase-1 (FOLH1) is a novel target for antibody-based brachytherapy in Merkel cell carcinoma.
Ramirez-Fort MK, Meier-Schiesser B, Lachance K, Mahase SS, Church CD, Niaz MJ, Liu H, Navarro V, Nikolopoulou A, Kazakov DV, Contassot E, Nguyen DP, Sach J, Hadravsky L, Sheng Y, Tagawa ST, Wu X, Lange CS, French LE, Nghiem PT, Bander NH. Ramirez-Fort MK, et al. Among authors: bander nh. Skin Health Dis. 2021 Mar;1(1):e9. doi: 10.1002/ski2.9. Epub 2020 Nov 28. Skin Health Dis. 2021. PMID: 34541577 Free PMC article.
164 results